Inactive Instrument

News Cellectar Biosciences Inc Nasdaq

Equities

US15117F2039

End-of-day quote Nasdaq Other stock markets
- ^USD	-

Mar. 28	Roth MKM Raises Cellectar Biosciences' Price Target to $28 From $20, Retains Buy Rating	MT
Mar. 28	Oppenheimer Adjusts Cellectar Biosciences Price Target to $12 From $11, Maintains Outperform Rating	MT

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Roth MKM Raises Cellectar Biosciences' Price Target to $28 From $20, Retains Buy Rating	Mar. 28	MT
Oppenheimer Adjusts Cellectar Biosciences Price Target to $12 From $11, Maintains Outperform Rating	Mar. 28	MT
Transcript : Cellectar Biosciences, Inc., 2023 Earnings Call, Mar 27, 2024	Mar. 27
Cellectar Biosciences Reports Financial Results for Year Ended 2023 and Provides a Corporate Update	Mar. 27	AQ
Cellectar Biosciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 27	CI
Cellectar Biosciences to Announce 2023 Year End Earnings Results and Host a Conference Call on Wednesday, March 27, 2024	Mar. 20	AQ
Cellectar Biosciences : Corporate Presentation - March 2024	Mar. 18	PU
Cellectar Biosciences to Present at the 36th Annual Roth Conference	Mar. 14	AQ
Cellectar Biosciences Reports High Rate of Complete Remission in Investigator Initiated Phase I Study of Iopofosine in Combination with External Beam Radiotherapy in Recurrent Head and Neck Cancer	Mar. 04	AQ
Cellectar Biosciences, Inc. Reports High Rate of Complete Remission in Investigator Initiated Phase I Study of iopofosine in Combination with External Beam Radiotherapy in Recurrent Head and Neck Cancer	Mar. 04	CI
Cellectar Biosciences to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference	Feb. 07	AQ
Cellectar Biosciences Announces Enrollment of the First Patient in Pediatric High-Grade Gliomas Phase 1b Clinical Study	Jan. 30	AQ
Cellectar Biosciences, Inc. Announces Enrollment of the First Patient in Pediatric High-Grade Gliomas Phase 1B Clinical Study	Jan. 30	CI
Cellectar Biosciences Announces Tranche A Warrants Fully Exercised, Providing Proceeds of $44.1 Million	Jan. 25	AQ
Cellectar Biosciences Reports Complete Central Nervous System Clearance in Relapsed, Refractory Waldenstrom's Macroglobulinemia Patient	Jan. 23	AQ
Sector Update: Health Care Stocks Advance Late Afternoon	Jan. 22	MT
Cellectar Biosciences Shares Rise as Drug Shows Promise on Complete Central Nervous System Clearance on Cancer Type	Jan. 22	MT
Cellectar Biosciences Reports Complete Central Nervous System (CNS) Clearance in Relapsed/Refractory Waldenstrom’s Macroglobulinemia Patient	Jan. 22	AQ
Cellectar Biosciences, Inc. Reports Complete Central Nervous System Clearance in Relapsed/Refractory Waldenstrom?s Macroglobulinemia Patient	Jan. 22	CI
Transcript : Cellectar Biosciences, Inc. - Special Call	Jan. 19

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Cellectar Biosciences Inc Nasdaq

Equities

US15117F2039

Summary

Filters